Skip to main content
PMC home page
Frontiers in Neuroscience logoLink to Frontiers in Neuroscience
. 2015 Jan 21;9:1. doi: 10.3389/fnins.2015.00001

Computational neurobiology is a useful tool in translational neurology: the example of ataxia

Sherry-Ann Brown 1,*, Louise D McCullough 2, Leslie M Loew 3
PMCID: PMC4300942  PMID: 25653585

Abstract

Hereditary ataxia, or motor incoordination, affects approximately 150,000 Americans and hundreds of thousands of individuals worldwide with onset from as early as mid-childhood. Affected individuals exhibit dysarthria, dysmetria, action tremor, and diadochokinesia. In this review, we consider an array of computational studies derived from experimental observations relevant to human neuropathology. A survey of related studies illustrates the impact of integrating clinical evidence with data from mouse models and computational simulations. Results from these studies may help explain findings in mice, and after extensive laboratory study, may ultimately be translated to ataxic individuals. This inquiry lays a foundation for using computation to understand neurobiochemical and electrophysiological pathophysiology of spinocerebellar ataxias and may contribute to development of therapeutics. The interdisciplinary analysis suggests that computational neurobiology can be an important tool for translational neurology.

Keywords: spinocerebellar ataxia; translational; model; computational; neurology; inositol 1,4,5-triphosphate receptor 1; Purkinje; homer

Introduction

Computational systems neurobiology (Brown et al., 2012) can be used to understand neuronal systems, based on utilizing information garnered from clinical reports, animal studies and in vitro modeling. Results from computational neurobiology can be used to develop additional animal and cellular experiments that may ultimately be translated to clinical practice, i.e., translational neurology. One clinical condition poised to benefit from this marriage is spinocerebellar ataxia (SCA) (Figure 1). Ataxia refers to lack of motor coordination (Goetz, 2003). In this paper, we use SCA as an example to demonstrate how computation and translation can potentially be woven together to enhance our knowledge of cell function.

Figure 1.

Figure 1

Open in a new tab

Translational neurology: ataxia. SCA mouse observations and human SCA findings are incorporated into the computational framework SCA modeling suite. The models help interpret experimental and clinical findings. The models also predict interactions between proteins and emergent properties that can be borne out in novel mouse experiments. Results from the laboratory and clinical observations can be used to validate, disprove, or tweak the computational models. Findings from mouse experiments can also ultimately be translated to human studies, leading to clinical trials to test therapeutics. The final step in translational neurology with the example of ataxia is implementation of the iterative findings in patient care. The solid square bracket highlights the components addressed directly by computational systems neurobiology (Brown et al., 2012; Brown and Loew, 2012).

The most common SCAs are spinocerebellar ataxia 1 (SCA1), spinocerebellar ataxia 2 (SCA2), spinocerebellar ataxia 3 (SCA3), and Spinocerebellar Ataxia 6 (SCA6) (Supplementary Material, Table S1) (Jacobi et al., 2012; Orr, 2012; Musova et al., 2013). They are caused by expanded polyglutamine (polyQ; CAG) repeat mutations in genes that code for ataxin 1, ataxin 2, ataxin 3, and the CACNA1A calcium channel, respectively (Supplementary Material, Table S1) (Gispert et al., 1993; Orr et al., 1993; Kawaguchi et al., 1994; Pulst et al., 1996; Zhuchenko et al., 1997; Tonelli et al., 2006; Bürk et al., 2014).

A number of mutations that cause SCA or episodic spinocerebellar ataxia (EA) also occur in genes directly involved in calcium signaling and plasma membrane excitability, which are critical for cerebellar Purkinje neuron function (Kim et al., 1997; Yue et al., 1997; Zhuchenko et al., 1997; Guida et al., 2001; Alonso et al., 2005; Iwaki et al., 2008; Becker et al., 2009; Alviña and Khodakhah, 2010; Kasumu and Bezprozvanny, 2012) (Supplementary Material, Table S1). A number of these genes impact the phosphoinositol signaling pathway (Supplementary Material, Figure S1A; Table S1) (Aiba et al., 1994; Kim et al., 1997; Alonso et al., 2005; van de Leemput et al., 2007). This pathway is important for calcium release from the smooth endoplasmic reticulum (sER) into the cytoplasm of cerebellar Purkinje neurons. Many other mutations affect calcium and potassium ion channels (EA2, SCA6, EA1, EA5, SCA13, SCA19, SCA22) (Supplementary Material, Table S1) (Yue et al., 1997; Zhuchenko et al., 1997; Lin et al., 2000; Guida et al., 2001; Imbrici et al., 2003; Sausbier et al., 2004; Tonelli et al., 2006; Bürk et al., 2014) that are important for regulating the rate of calcium influx into cells. spinocerebellar ataxia 14 (SCA14) involves a mutation in the gene encoding protein kinase C (PKC) that is also important for calcium homeostasis (Supplementary Material, Figure S1A; Table S1) (Alonso et al., 2005; Ueda et al., 2013; van Gaalen et al., 2013; Ji et al., 2014). spinocerebellar ataxia 15 (SCA15) and spinocerebellar ataxia 16 (SCA16) in humans and in mice are caused by deletion and missense mutations in the gene for inositol-1,4,5-trisphosphate receptor type 1 (IP3R1), a calcium channel on the sER (Desaiah et al., 1991; Street et al., 1997; Zecevic et al., 1999; Lin et al., 2000; Storey et al., 2001; Serra et al., 2004; van de Leemput et al., 2007; Chen et al., 2008; Chou et al., 2008; Hara et al., 2008; Iwaki et al., 2008; Liu et al., 2009; Di Gregorio et al., 2010; Novak et al., 2010a,b; Huang et al., 2012).

Data from mouse experiments and clinical observations have been incorporated into SCA computational models (Brown and Loew, 2015). The models are developed using computer engineering tools and software, such as Virtual Cell (Moraru et al., 2008; Slepchenko and Loew, 2010) and NEURON (Hines and Carnevale, 2001). These modeling platforms are based on mathematical equations for physics principles, such as reaction, diffusion, flux, and concentration gradients (Hines and Carnevale, 1997; Schaff et al., 2000; Cowan et al., 2012). The models simulate physiological interactions among intracellular reactions, molecular diffusion, and cell geometry and give insight into how these cellular processes work together as an efficient system (Brown et al., 2008; Brown and Loew, 2012). Simulations help clarify observed phenomena and suggest future experiments to help elucidate disease mechanisms and potential therapeutics.

Experiments confirm model predictions

There are a handful of neurobiological and electrophysiological computational models relevant to IP3R1-associated ataxias (Brown and Loew, 2012), detailed in the following subsections.

Neurobiology modeling and simulation

PIP2 signaling upstream of IP3R1

First, a model of phosphatidylinositol-4,5-bisphosphate (PIP2) signaling upstream of IP3R1 in neuroblastoma cells was developed (Xu et al., 2003) (Supplementary Material, Figure S1A). The model predicted stimulated PIP2 synthesis in addition to PIP2 hydrolysis when the Purkinje neuron spine is activated by parallel fibers, to produce IP3R1-mediated calcium release. Subsequently, bench experiments confirmed simulation results in a mouse neuroblastoma cell line (Xu et al., 2003).

IP3R1 signaling downstream of PIP2

Second, models of IP3R1-related signaling downstream of PIP2 in the cerebellar Purkinje neuron were created (Doi et al., 2003; Hernjak et al., 2005). One model considered the high abundance and low sensitivity of IP3R1 in Purkinje cells (Hernjak et al., 2005). This model qualitatively reproduced experimentally observed calcium transients during coincident activation of the Purkinje spiny dendrite (Wang et al., 2000).

Sources of sufficient PIP2 for IP3R1-mediated signaling

Third, quantitative models of Purkinje neurons spiny dendrites were developed (Brown et al., 2008, 2011; Brown and Loew, 2012). Local sequestration of PIP2 (with a lower diffusion coefficient than unbound PIP2) on the inner leaflet of cerebellar Purkinje neuron spines (McLaughlin et al., 2002; Golebiewska et al., 2008) (Supplementary Material, Figure S1B) was assessed. Model results supported the efficacy of local sequestration as a means of providing sufficient PIP2 for IP3R1-mediate calcium release. Findings correlated with prior experimental results (Wang et al., 2000) (Table 1). The computational simulations predicted a time window during which coincident activation of the Purkinje spine by other cell types could occur (Brown et al., 2008). This time window was independently borne out in bench experiments in rat cerebellar brain slices (Sarkisov and Wang, 2008) (Table 1).

Table 1.

Examples of contributions of computational systems neurobiology to translational neurology.

Mechanism elucidated Computational prediction Supporting experiments References (Computational/Experiment)
Source of requisite IP3 PIP2 synthesis concurrent with hydrolysis IP3 production in neuroblastoma cells Xu et al., 2003/Xu et al., 2003
Purkinje spine electrophysiology D-type K and class-E Ca channels required Purkinje neuron current clamp Miyasho et al., 2001/Miyasho et al., 2001
Biochemical-electrical cross-talk Emergent cross-signaling properties Biochemical before electrical changes in SCA2 mice Brown and Loew, 2012/Hansen et al., 2013
AMPAR all-or-none activation MAPK-PKC positive feedback loop Purkinje stimulation by CFs/PFs Ogasawara et al., 2008/Ogasawara et al., 2008
Local PIP2 sequestration Fine-tunes coincidence detection Purkinje stimulation by CFs/PFs Brown et al., 2008/Wang et al., 2000
Coincidence detection 50–100 ms time window CF before PF Purkinje stimulation by CFs/PFs Brown et al., 2008/Sarkisov and Wang, 2008
IP3R1 compensation IP3R1 downregulation in polyQ disorders with IP3R1 supersensitivity IP3R1 (and other members of the signaling complex*) downregulation in DLPRA Brown and Loew, 2012/Suzuki et al., 2012
Open in a new tab
*

(Supplementary Material, S1 Signaling complex regulation).

Signaling downstream of IP3R1

Fourth, predictions were generated about kinetic interactions between PKC and α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype glutamate receptors (AMPAR) in Purkinje neurons that were experimentally verified (Ogasawara et al., 2008) (Table 1). These molecules are downstream of IP3R1-mediated calcium release, as calcium co-activates PKC.

Potential use of neurobiological model results

Using results from these computational models, drugs could be developed to interfere with local sequestration or other steps in the phosphoinositol signaling pathway in mice or rats and could potentially be translated to humans with supersensitive IP3R1 to help treat SCA1-3 and SCA14 (Supplementary Material, Table S1).

Neuroelectrophysiology modeling

Prediction of purkinje neuron calcium and potassium channels

Normal electrophysiology of the Purkinje neuron was also modeled (De Schutter and Bower, 1994a,b; Miyasho et al., 2001). New properties of Purkinje neuron electrophysiology were predicted, requiring contributions of D-type potassium channels and class-E calcium channels that were not known previously to influence Purkinje neuron electrophysiology (Supplementary Material, Figure S1A). The predictions were confirmed with rat model experiments (Miyasho et al., 2001) (Table 1).

Reduction of purkinje neurons

A method to map realistic neurons into equivalent reduced models while maintaining high accuracy membrane potential changes during synaptic inputs, with direct links to experimental observables was subsequently developed (Marasco et al., 2012).

Potential use of neuroelectrophysiological model results

The examples provided suggest that iterative computational modeling can provide insight into normal and pathological neurophysiology. The neuroelectrophysiology models could be used to economically assess the impact of new therapeutics in research and development prior to studies in mice or rats. Manipulation in the virtual system would allow for precise input control and real-time output review with changes in firing dynamics of the Purkinje neuron. This would facilitate discovery of determinant and feedback loops (Brown and Loew, 2015) and other interactions that would otherwise be impossible to monitor in brain slices in the same time frame. Insights could potentially be translated to humans with various SCAs, particularly those such as SCA6, SCA13, SCA19, and SCA22 that involve disruption of membrane electrophysiology (Supplementary Material, Table S1).

Simulations interpret observed phenotypes

Supranormal IP3R1 sensitivity in SCA 1-3

A source of pathology caused by the polyQ repeats (Orr et al., 1993; Kawaguchi et al., 1994; Koide et al., 1994, 1999; Trottier et al., 1994; Pulst et al., 1996; David et al., 1997; Nakamura et al., 2001) is due to interaction of the mutant protein with IP3R1 (Bezprozvanny, 2011). In SCA2 (Liu et al., 2009) and SCA3 (Chen et al., 2008), mutant Ataxin-2 and Ataxin-3, respectively, directly bind to the C-terminal of IP3R1 and make it easier to solicit IP3-induced calcium responses. Association of mutant Ataxin-1 with IP3R1 has been reported (Liu et al., 2009), but supersensitivity in these mice has not yet been tested. SCA modeling results suggests that IP3R1 supersensitivity in SCA1 is necessary (Brown and Loew, 2012) to elicit observed supranormal calcium transients (Inoue et al., 2001).

IP3R1 downregulation provides partial compensation in SCA 1-3

Studies in SCA1 and SCA2 mouse models, as well as mice and humans with SCA3, found reduced levels of IP3R1, metabotropic glutamate receptor (mGluR), and other calcium signaling and glutamatergic proteins (Lin et al., 2000; Vig et al., 2001; Serra et al., 2004; Chou et al., 2008; Hansen et al., 2013) (Supplementary Material, Figure S1). Decreased expression of IP3R1 and sarcoendoplasmic reticulum calcium ATPase (SERCA) was also confirmed in SCA1 patients (Lin et al., 2000). Such findings were also discovered in Purkinje neurons from mouse models of HD (Datta et al., 2011; Euler et al., 2012). SCA modeling interprets downregulation of these key calcium signaling proteins as serving to partially compensate for supersensitive IP3R1 (Brown and Loew, 2012). Further downregulation of these glutamatergic signaling proteins could be manipulated to delay symptomatic disease in mouse models and in the long run in presymptomatic humans (Brown and Loew, 2015).

Homer and myosin VA association with IP3R1 in SCAs

Homer 3 is part of a signaling complex with reduced expression in SCA1 mice (Serra et al., 2004) (Supplementary Material, S1 Signaling complex regulation). Homer 3 localizes predominantly to Purkinje neuron spines (Shiraishi et al., 2004) and may associate with mGluR and IP3R1 in vivo (Tu et al., 1998; Sandonà et al., 2003). Myosin Va levels are also decreased in SCA1 (Serra et al., 2004). Both Homer and Myosin Va have been proposed to guide sER (sER) into spines as spines are being formed from dendritic shafts (Wagner and Hammer, 2003). Accordingly, Myosin Va knockout mice are ataxic with spines devoid of sER and IP3R1 (Takagishi et al., 1996). SCA modeling results suggest that reduced spine sER volume due to downregulation of Homer 3 and Myosin Va in SCA1 partially compensates for IP3R1 supersensitivity (Brown and Loew, 2012). This supports findings from an experiment in which downregulation of Homer 1b/c attenuated IP3R1-mediated calcium release in rat cortical neurons (Chen et al., 2012). Expression of Homer could potentially be manipulated to further compensate for IP3R1 supersensitivity in polyQ ataxias, which also include SCA7 (David et al., 1997), SCA17 (Nakamura et al., 2001), and dentatorubral-pallidoluysian atrophy (DLPRA) (Koide et al., 1994). SCA simulations could determine a therapeutic window for Homer expression to avoid overcompensation. As an example, although a very different mechanism, Homer 3 scaffolding protein has been implicated as an autoimmune target in subacute cerebellar ataxia. This ataxia is not hereditary and occurs post-infection or as a paraneoplastic process in some patients with Hodgkin's lymphoma (Zuliani et al., 2007). Presumably, disruption of Homer 3 scaffolding beyond a therapeutic window, or in the absence of supersensitive IP3R1 as in autoimmune subacute cerebellar ataxia, interrupts signaling complex formation and related cellular processes (Supplementary Material, S1 Signaling complex regulation).

Cross-signaling between biochemical and electrophysiological dysregulation in SCAs

These and other forms of biochemical dysregulation precede electrophysiological impairment in an SCA2 mouse model, with Purkinje neuron firing frequency decreased at 6 weeks compared to wild type (Hansen et al., 2013) and worsening as the mice age (Kasumu et al., 2012b). This is consistent with timing of electrophysiological changes in an SCA1 mouse model (Hourez et al., 2011) and in the large conductance calcium-activated voltage-gated potassium channel (BK) knockout mice (Sausbier et al., 2004). These changes are then followed by onset of motor discoordination at 8 weeks in the SCA2 mice (Hansen et al., 2013) and 6–8 weeks in SCA3 mice (Shakkottai et al., 2011). The time of ataxia onset for these mice is identical to that for mice heterozygous for IP3R1 deletion (Ogura et al., 2001). These findings imply shared pathophysiology leading to similar phenotype: biochemical dysfunction and subsequent electrophysiological aberrations leading to ataxia. The SCA modeling suite has also predicted altered Purkinje neuron firing arising from cross-talk between calcium signaling and membrane electrophysiology (Brown and Loew, 2012) (Table 1). Future iterations of the modeling suite could additionally include the small conductance calcium-activated potassium channels (SK), which has been shown to help mediate the influence of calcium signaling on membrane electrophysiology in SCA2 and EA, and has also been proposed as a potential therapeutic targets (Alviña and Khodakhah, 2010; Kasumu et al., 2012a).

Clinical translation

Computational models are clinically informative for SCAs

The cerebellum is conserved across all vertebrate species (Kandel et al., 2000). Thus, a combination of computational models and mouse models is clinically informative for human SCAs. Several SCA mouse models have been developed (Burright et al., 1995; Huynh et al., 2000; van de Leemput et al., 2007; Colomer Gould, 2012; Kelp et al., 2013). As virtual model neurons are created, details of the computational models are validated by comparison with experimental data in these mice (Xu et al., 2003; Marasco et al., 2012), with an end to translation to humans (Figure 1).

ICpeptide application in vivo for SCAs and other polyQ diseases

Peptides resembling portions of the IP3R1 C-terminal (ICpeptides) (Supplementary Material, Figure S1B) have been created (Tang et al., 2003b, 2009; Tu et al., 2004). SCA model results suggest that application of IC-G2736X (IP3R1 base pairs D2590-G2736) (Supplementary Material, Figure S1B) restores normal calcium transients in polyQ ataxias (Brown and Loew, 2012). ICpeptides could be used to develop more selective therapeutics that can then be tested in animals and, if promising, in patients. Simulations also showed that treating SCA15/16 mice with IC4 (IP3R1 base pairs Q2714-A2749) normalizes calcium release by therapeutically increasing IP3R1 sensitivity to IP3 to counteract IP3R1 haploinsufficiency (Brown and Loew, 2012). IC4 competitively binds protein phosphatase 1 alpha (PP1α; a phosphatase that decreases IP3R1 sensitivity).

A different polyQ disorder, Huntington's disease (HD), is sometimes phenotypically confused with SCA if ataxia is prominent (Tang et al., 2003a; Bezprozvanny and Hayden, 2004; Bezprozvanny, 2007; Zhang et al., 2008; Dong et al., 2013; Rodríguez-Quiroga et al., 2013). Whereas ataxias primarily exhibit motor discoordination, HD is a neurodegenerative hyperkinetic movement disorder affecting the basal ganglia (Bezprozvanny, 2011). Although molecular interactions in Purkinje neurons are different from those in medial striatal neurons, the polyQ SCAs share underlying pathophysiology with HD involving supersensitive IP3R1 (Bezprozvanny, 2011). Application of the IC10 peptide (IP3R1 base pairs F2627-A2749) (Supplementary Material, Figure S1B) in medial striatal neurons in HD mice restored normal calcium response (Tang et al., 2009). These mice were largely spared from neurotoxicity, with improved motor coordination (Tang et al., 2009). IC-peptides therefore represent an alternative step toward thinking about new therapeutics for polyQ disorders.

IP3 suppression in SCAs

Subsequent to these simulations (Brown and Loew, 2012), it was demonstrated that overexpressing inositol 1,4,5-phosphatase (5PP) to chronically suppress IP3R1-mediated calcium release improved motor coordination in SCA2 mice (Kasumu et al., 2012b). The enzyme 5PP converts IP3 to the inactive form inositol 1,4-bisphosphatase (Supplementary Material, Figure S1A), decreasing the overall amount of IP3 sensed by IP3R1. This demonstrated that suppression of IP3R1-mediated calcium release could be of therapeutic benefit for SCAs, as supported by SCA modeling predictions (Figure 1).

Anticipatory therapeutics for SCAs

There is currently no direct way of treating hereditary ataxias. Patients can be cared for symptomatically, with physical and speech therapy and walking aids (Schöls et al., 2004). If SCA modeling can help us understand how alterations in calcium signaling and membrane electrophysiology can be restored in SCAs, this can enhance our chance at engineering therapeutics for ataxia. In the era of SCA genomic testing (Smeets and Verbeek, 2014), anticipatory therapeutics would be useful preferentially in presymptomatic patients (Brown and Loew, 2015). For example, if ICpeptides are applied before mice become symptomatic, this could reduce symptom occurrence, delay onset, slow progression, and maximize output from undamaged tissue. SCA modeling would therefore be integrated with genomic testing, family history considerations, and presymptomatic investigation and treatment. Presymptomatic testing is often pursued for severe late-onset neurodegenerative diseases, including SCAs (Guimarães et al., 2013; Schuler-Faccini et al., 2014). Even without genetic testing, other early clinical disease features (prodromes) are detectable prior to onset of ataxia and can be used to determine treatment timing (Velázquez-Pérez et al., 2014a,b). Such translation, after extensive lab research, could improve quality of life and alleviate economical, social, and occupational strains on patients, as well as family members and caregivers.

Uses for SCA modeling exemplified

In computational models, various parameters in the cerebellar Purkinje neuron may be deliberately perturbed, with results examined to see if any of these perturbations match those found in individuals with various cerebellar disorders. This can assist with making connections between subcellular dysfunction and phenotypic manifestations. In addition to understanding pathophysiology, the models could be used to screen drugs, investigate adverse effects, and examine ramifications of genetic replacements and knockouts.

There are other computational models that can be used to exemplify the potential of SCA models. Experiment-based computational modeling similar to SCA, including the use of individualized 3D reconstruction of in vivo-acquired computed tomography (CT) images from several patients, showed that peak wall stress calculated in vivo for abdominal aortic aneurysm (AAA) near the time of rupture was more predictive of rupture than the conventional assessment of aortic diameter (Fillinger et al., 2002; Raut et al., 2013; Soudah et al., 2013). Similarly, Caroli et al used computational modeling to create patient-specific computational vascular network models (Caroli et al., 2013). These models predicted blood flow 6 weeks after surgical creation of arteriovenous fistulas (AVF) for long-term hemodialysis (Caroli et al., 2013). The model was validated in a multicenter, prospective clinical study, and is expected to reduce AVF failure or dysfunction and related patient morbidity. A line of computational models were also created to compare various modes of pharmacologic delivery of Doxorubicin, a chemotherapeutic drug used for a variety of cancers. The models predicted optimal antitumor efficacy with protection from adverse effects with thermosensitive liposomes or with an administration protocol using increased duration of infusion with higher doses, compared to the conventional bolus injection (Reich et al., 1979; El-Kareh and Secomb, 2000, 2005; Evans et al., 2009; Zhan and Xu, 2013).

Systems biology in translational medicine

A number of scientific contributions from computational modeling (Table 1) that enhance our understanding of SCA have been presented. The computational models are more economical, reproducible, and expedient than animal experiments. However, the computer models depend on and integrate information from animal studies and clinical observations. As a result, Figure 1 shows that animal experiments and SCA models work together in concert to iteratively explain and predict pathophysiology. In addition, computational predictions were made via a bioinformatics screen to identify transcripts that interact with and have functions relevant to polyQ SCAs (Spence and Wallihan, 2012). Next steps in translational systems biology will include mining and modeling network motifs in ataxia and considering their functional implications (Alon, 2007; Brown and Loew, 2015). Findings from such translational studies could be used to develop new drugs or treatment strategies (Matilla-Dueñas et al., 2014), suggesting that computational neurobiology plays a role in translational neurology (Figure 1). Expanding interactions between these related research and medical communities (De Schutter, 2008) will usher in an era that may create advanced support for Translational Medicine and, in particular, Neurology.

Author contributions

Sherry-Ann Brown conceived of, analyzed, designed, drafted, critically revised, approved, and agreed to be accountable for this submitted work. Louise D. McCullough conceived of, critically revised, approved, and agreed to be accountable for this submitted work. Leslie M. Loew analyzed, critically revised, approved, and agreed to be accountable for this submitted work.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary material

The Supplementary Material for this article can be found online at: http://www.frontiersin.org/journal/10.3389/fnins.2015.00001/abstract

Click here for additional data file. (128.3KB, DOCX)
Click here for additional data file. (2.3MB, TIF)
Click here for additional data file. (3.3MB, TIF)

References

  1. Aiba A., Kano M., Chen C., Stanton M., Fox G., Herrup K., et al. (1994). Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice. Cell 79, 377–388. 10.1016/0092-8674(94)90205-4 [DOI] [PubMed] [Google Scholar]
  2. Alon U. (2007). Network motifs: theory and experimental approaches. Nat. Rev. Genet. 8, 450–461. 10.1038/nrg2102 [DOI] [PubMed] [Google Scholar]
  3. Alonso I., Costa C., Gomes A., Ferro A., Seixas A., Silva S., et al. (2005). A novel H101Q mutation causes PKCgamma loss in spinocerebellar ataxia type 14. J. Hum. Genet. 50, 523–529. 10.1007/s10038-005-0287-z [DOI] [PubMed] [Google Scholar]
  4. Alviña K., Khodakhah K. (2010). KCa channels as therapeutic targets in episodic ataxia Type-2. J. Neurosci. 30, 7249–7257. 10.1523/JNEUROSCI.6341-09.2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Becker E., Oliver P., Glitsch M., Banks G., Achilli F., Hardy A., et al. (2009). A point mutation in TRPC3 causes abnormal Purkinje cell development and cerebellar ataxia in moonwalker mice. Proc. Natl. Acad. Sci. U.S.A. 106, 6706–6711. 10.1073/pnas.0810599106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bezprozvanny I. (2007). Inositol 1,4,5-tripshosphate receptor, calcium signalling and Huntington's disease. Subcell. Biochem. 45, 323–335. 10.1007/978-1-4020-6191-2_11 [DOI] [PubMed] [Google Scholar]
  7. Bezprozvanny I. (2011). Role of inositol 1,4,5-trishosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias. Neurochem. Res. 36, 1186–1197. 10.1007/s11064-010-0393-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bezprozvanny I., Hayden M. (2004). Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun. 322, 1310–1317. 10.1016/j.bbrc.2004.08.035 [DOI] [PubMed] [Google Scholar]
  9. Brown S.-A., Holmes R., Loew L. M. (2012). Spatial organization and diffusion in neuronal signaling, in Computational Systems Neurobiology, ed Novere N. L. (Dordrecht: Springer; ), 133–161. [Google Scholar]
  10. Brown S. A., Loew L. M. (2012). Computational analysis of calcium signaling and membrane electrophysiology in cerebellar Purkinje neurons associated with ataxia. BMC Syst. Biol. 6:70. 10.1186/1752-0509-6-70 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Brown S.-A., Loew L. M. (2015). Inositol 1,4,5-trisphosphate receptor 1 is essential to spinocerebellar ataxia modeling. Front. Neurosci. 8:453 10.3389/fnins.2014.00453 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Brown S. A., Moraru I. I., Schaff J. C., Loew L. M. (2011). Virtual NEURON: a strategy for merged biochemical and electrophysiological modeling. J. Comput. Neurosci. 31, 385–400. 10.1007/s10827-011-0317-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Brown S., Morgan F., Watras J., Loew L. (2008). Analysis of phosphatidylinositol-4,5-bisphosphate signaling in cerebellar Purkinje spines. Biophys. J. 95, 1795–1812. 10.1529/biophysj.108.130195 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Bürk K., Kaiser F. J., Tennstedt S., Schöls L., Kreuz F. R., Wieland T., et al. (2014). A novel missense mutation in CACNA1A evaluated by in silico protein modeling is associated with non-episodic spinocerebellar ataxia with slow progression. Eur. J. Med. Genet. 57, 207–211. 10.1016/j.ejmg.2014.01.005 [DOI] [PubMed] [Google Scholar]
  15. Burright E., Clark H., Servadio A., Matilla T., Feddersen R., Yunis W., et al. (1995). SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82, 937–948. 10.1016/0092-8674(95)90273-2 [DOI] [PubMed] [Google Scholar]
  16. Caroli A., Manini S., Antiga L., Passera K., Ene-Iordache B., Rota S., et al. (2013). Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. Kidney Int. 84, 1237–1245. 10.1038/ki.2013.188 [DOI] [PubMed] [Google Scholar]
  17. Chen T., Fei F., Jiang X. F., Zhang L., Qu Y., Huo K., et al. (2012). Down-regulation of Homer1b/c attenuates glutamate-mediated excitotoxicity through endoplasmic reticulum and mitochondria pathways in rat cortical neurons. Free Radic. Biol. Med. 52, 208–217. 10.1016/j.freeradbiomed.2011.10.451 [DOI] [PubMed] [Google Scholar]
  18. Chen X., Tang T., Tu H., Nelson O., Pook M., Hammer R., et al. (2008). Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J. Neurosci. 28, 12713–12724. 10.1523/JNEUROSCI.3909-08.2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Chou A., Yeh T., Ouyang P., Chen Y., Chen S., Wang H. (2008). Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol. Dis. 31, 89–101. 10.1016/j.nbd.2008.03.011 [DOI] [PubMed] [Google Scholar]
  20. Colomer Gould V. F. (2012). Mouse models of spinocerebellar ataxia type 3 (Machado-Joseph disease). Neurotherapeutics 9, 285–296. 10.1007/s13311-012-0117-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Cowan A. E., Moraru I. I., Schaff J. C., Slepchenko B. M., Loew L. M. (2012). Spatial modeling of cell signaling networks. Methods Cell Biol. 110, 195–221. 10.1016/B978-0-12-388403-9.00008-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Datta M., Choudhury A., Lahiri A., Bhattacharyya N. P. (2011). Genome wide gene expression regulation by HIP1 Protein Interactor, HIPPI: prediction and validation. BMC Genomics 12:463. 10.1186/1471-2164-12-463 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. David G., Abbas N., Stevanin G., Dürr A., Yvert G., Cancel G., et al. (1997). Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat. Genet. 17, 65–70. 10.1038/ng0997-65 [DOI] [PubMed] [Google Scholar]
  24. Desaiah D., Vig P., Subramony S., Currier R. (1991). Inositol 1,4,5-trisphosphate receptors and protein kinase C in olivopontocerebellar atrophy. Brain Res. 552, 36–40. 10.1016/0006-8993(91)90656-G [DOI] [PubMed] [Google Scholar]
  25. De Schutter E. (2008). Why are computational neuroscience and systems biology so separate? PLoS Comput. Biol. 4:e1000078. 10.1371/journal.pcbi.1000078 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. De Schutter E., Bower J. (1994a). An active membrane model of the cerebellar Purkinje cell II. Simulation of synaptic responses. J. Neurophysiol. 71, 401–419. [DOI] [PubMed] [Google Scholar]
  27. De Schutter E., Bower J. (1994b). An active membrane model of the cerebellar Purkinje cell. I. Simulation of current clamps in slice. J. Neurophysiol. 71, 375–400. [DOI] [PubMed] [Google Scholar]
  28. Di Gregorio E., Orsi L., Godani M., Vaula G., Jensen S., Salmon E., et al. (2010). Two Italian families with ITPR1 gene deletion presenting a broader phenotype of SCA15. Cerebellum. 9, 115–123. 10.1007/s12311-009-0154-0 [DOI] [PubMed] [Google Scholar]
  29. Doi T., Kuroda S., Michikawa T., Kawato M. (2003). [Simulation of IP3/Ca2+ signaling pathway in neurons: the system of coincidence detection of input timing in cerebellar Purkinje cells]. Tanpakushitsu Kakusan Koso 48, 817–822. [PubMed] [Google Scholar]
  30. Dong Y., Sun Y. M., Liu Z. J., Ni W., Shi S. S., Wu Z. Y. (2013). Chinese patients with Huntington's disease initially presenting with spinocerebellar ataxia. Clin. Genet. 83, 380–383. 10.1111/j.1399-0004.2012.01927.x [DOI] [PubMed] [Google Scholar]
  31. El-Kareh A. W., Secomb T. W. (2000). A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells. Neoplasia 2, 325–338. 10.1038/sj.neo.7900096 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. El-Kareh A. W., Secomb T. W. (2005). Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin. Neoplasia 7, 705–713. 10.1593/neo.05118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Euler P., Friedrich B., Ziegler R., Kuhn A., Lindenberg K. S., Weiller C., et al. (2012). Gene expression analysis on a single cell level in Purkinje cells of Huntington's disease transgenic mice. Neurosci. Lett. 517, 7–12. 10.1016/j.neulet.2012.03.080 [DOI] [PubMed] [Google Scholar]
  34. Evans C. J., Phillips R. M., Jones P. F., Loadman P. M., Sleeman B. D., Twelves C., et al. (2009). A mathematical model of doxorubicin penetration through multicellular layers. J. Theor. Biol. 257, 598–608. 10.1016/j.jtbi.2008.11.031 [DOI] [PubMed] [Google Scholar]
  35. Fillinger M. F., Raghavan M. L., Marra S. P., Cronenwett J. L., Kennedy F. E. (2002). In vivo analysis of mechanical wall stress and abdominal aortic aneurysm rupture risk. J. Vasc. Surg. 36, 589–597. 10.1067/mva.2002.125478 [DOI] [PubMed] [Google Scholar]
  36. Gispert S., Twells R., Orozco G., Brice A., Weber J., Heredero L., et al. (1993). Chromosomal assignment of the second locus for autosomal dominant cerebellar ataxia (SCA2) to chromosome 12q23-24.1. Nat. Genet. 4, 295–299. 10.1038/ng0793-295 [DOI] [PubMed] [Google Scholar]
  37. Goetz C. G. (2003). Textbook of Clinical Neurology. St. Louis, MO: WB Saunders. [Google Scholar]
  38. Golebiewska U., Nyako M., Woturski W., Zaitseva I., McLaughlin S. (2008). Diffusion coefficient of fluorescent phosphatidylinositol 4,5-bisphosphate in the plasma membrane of cells. Mol. Biol. Cell 19, 1663–1669. 10.1091/mbc.E07-12-1208 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Guida S., Trettel F., Pagnutti S., Mantuano E., Tottene A., Veneziano L., et al. (2001). Complete loss of P/Q calcium channel activity caused by a CACNA1A missense mutation carried by patients with episodic ataxia type 2. Am. J. Hum. Genet. 68, 759–764. 10.1086/318804 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Guimarães L., Sequeiros J., Skirton H., Paneque M. (2013). What counts as effective genetic counselling for presymptomatic testing in late-onset disorders? A study of the consultand's perspective. J. Genet. Couns. 22, 437–447. 10.1007/s10897-012-9561-3 [DOI] [PubMed] [Google Scholar]
  41. Hansen S. T., Meera P., Otis T. S., Pulst S. M. (2013). Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2. Hum. Mol. Genet. 22, 271–283. 10.1093/hmg/dds427 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Hara K., Shiga A., Nozaki H., Mitsui J., Takahashi Y., Ishiguro H., et al. (2008). Total deletion and a missense mutation of ITPR1 in Japanese SCA15 families. Neurology 71, 547–551. 10.1212/01.wnl.0000311277.71046.a0 [DOI] [PubMed] [Google Scholar]
  43. Hernjak N., Slepchenko B., Fernald K., Fink C., Fortin D., Moraru I., et al. (2005). Modeling and analysis of calcium signaling events leading to long-term depression in cerebellar Purkinje cells. Biophys. J. 89, 3790–3806. 10.1529/biophysj.105.065771 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Hines M., Carnevale N. (1997). The NEURON simulation environment. Neural Comput. 9, 1179–1209. 10.1162/neco.1997.9.6.1179 [DOI] [PubMed] [Google Scholar]
  45. Hines M., Carnevale N. (2001). NEURON: a tool for neuroscientists. Neuroscientist 7, 123–135. 10.1177/107385840100700207 [DOI] [PubMed] [Google Scholar]
  46. Hourez R., Servais L., Orduz D., Gall D., Millard I., de Kerchove d'Exaerde A., et al. (2011). Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J. Neurosci. 31, 11795–11807. 10.1523/JNEUROSCI.0905-11.2011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Huang L., Chardon J. W., Carter M. T., Friend K. L., Dudding T. E., Schwartzentruber J., et al. (2012). Missense mutations in ITPR1 cause autosomal dominant congenital nonprogressive spinocerebellar ataxia. Orphanet J. Rare Dis. 7:67. 10.1186/1750-1172-7-67 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Huynh D., Figueroa K., Hoang N., Pulst S. (2000). Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat. Genet. 26, 44–50. 10.1038/79162 [DOI] [PubMed] [Google Scholar]
  49. Imbrici P., Cusimano A., D'Adamo M., De Curtis A., Pessia M. (2003). Functional characterization of an episodic ataxia type-1 mutation occurring in the S1 segment of hKv1.1 channels. Pflugers Arch. 446, 373–379. [DOI] [PubMed] [Google Scholar]
  50. Inoue T., Lin X., Kohlmeier K., Orr H., Zoghbi H., Ross W. (2001). Calcium dynamics and electrophysiological properties of cerebellar Purkinje cells in SCA1 transgenic mice. J. Neurophysiol. 85, 1750–1760. [DOI] [PubMed] [Google Scholar]
  51. Iwaki A., Kawano Y., Miura S., Shibata H., Matsuse D., Li W., et al. (2008). Heterozygous deletion of ITPR1, but not SUMF1, in spinocerebellar ataxia type 16. J. Med. Genet. 45, 32–35. 10.1136/jmg.2007.053942 [DOI] [PubMed] [Google Scholar]
  52. Jacobi H., Hauser T. K., Giunti P., Globas C., Bauer P., Schmitz-Hübsch T., et al. (2012). Spinocerebellar ataxia types 1, 2, 3 and 6: the clinical spectrum of ataxia and morphometric brainstem and cerebellar findings. Cerebellum 11, 155–166. 10.1007/s12311-011-0292-z [DOI] [PubMed] [Google Scholar]
  53. Ji J., Hassler M. L., Shimobayashi E., Paka N., Streit R., Kapfhammer J. P. (2014). Increased protein kinase C gamma activity induces Purkinje cell pathology in a mouse model of spinocerebellar ataxia 14. Neurobiol. Dis. 70C, 1–11. 10.1016/j.nbd.2014.06.002 [DOI] [PubMed] [Google Scholar]
  54. Kandel E., Schwartz J., Jessell T. (2000). ‘The Cerebellum,’ Principles of Neuroscience. New York, NY: McGraw Hill. [Google Scholar]
  55. Kasumu A., Bezprozvanny I. (2012). Deranged calcium signaling in purkinje cells and pathogenesis in spinocerebellar Ataxia 2 (SCA2) and other Ataxias. Cerebellum 11, 630–639. 10.1007/s12311-010-0182-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Kasumu A. W., Hougaard C., Rode F., Jacobsen T. A., Sabatier J. M., Eriksen B. L., et al. (2012a). Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. Chem. Biol. 19, 1340–1353. 10.1016/j.chembiol.2012.07.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Kasumu A. W., Liang X., Egorova P., Vorontsova D., Bezprozvanny I. (2012b). Chronic suppression of inositol 1,4,5-triphosphate receptor-mediated calcium signaling in cerebellar purkinje cells alleviates pathological phenotype in spinocerebellar ataxia 2 mice. J. Neurosci. 32, 12786–12796. 10.1523/JNEUROSCI.1643-12.2012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Kawaguchi Y., Okamoto T., Taniwaki M., Aizawa M., Inoue M., Katayama S., et al. (1994). CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat. Genet. 8, 221–228. 10.1038/ng1194-221 [DOI] [PubMed] [Google Scholar]
  59. Kelp A., Koeppen A. H., Petrasch-Parwez E., Calaminus C., Bauer C., Portal E., et al. (2013). A novel transgenic rat model for spinocerebellar ataxia type 17 recapitulates neuropathological changes and supplies in vivo imaging biomarkers. J. Neurosci. 33, 9068–9081. 10.1523/JNEUROSCI.5622-12.2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Kim D., Jun K., Lee S., Kang N., Min D., Kim Y., et al. (1997). Phospholipase C isozymes selectively couple to specific neurotransmitter receptors. Nature 389, 290–293. 10.1038/38508 [DOI] [PubMed] [Google Scholar]
  61. Koide R., Ikeuchi T., Onodera O., Tanaka H., Igarashi S., Endo K., et al. (1994). Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat. Genet. 6, 9–13. 10.1038/ng0194-9 [DOI] [PubMed] [Google Scholar]
  62. Koide R., Kobayashi S., Shimohata T., Ikeuchi T., Maruyama M., Saito M., et al. (1999). A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Hum. Mol. Genet. 8, 2047–2053. 10.1093/hmg/8.11.2047 [DOI] [PubMed] [Google Scholar]
  63. Lin X., Antalffy B., Kang D., Orr H., Zoghbi H. (2000). Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat. Neurosci. 3, 157–163. 10.1038/72101 [DOI] [PubMed] [Google Scholar]
  64. Liu J., Tang T., Tu H., Nelson O., Herndon E., Huynh D., et al. (2009). Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J. Neurosci. 29, 9148–9162. 10.1523/JNEUROSCI.0660-09.2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Marasco A., Limongiello A., Migliore M. (2012). Fast and accurate low-dimensional reduction of biophysically detailed neuron models. Sci. Rep. 2:928. 10.1038/srep00928 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Matilla-Dueñas A., Ashizawa T., Brice A., Magri S., McFarland K. N., Pandolfo M., et al. (2014). Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias. Cerebellum 13, 269–302. 10.1007/s12311-013-0539-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. McLaughlin S., Wang J., Gambhir A., Murray D. (2002). PIP(2) and proteins: interactions, organization, and information flow. Annu. Rev. Biophys. Biomol. Struct. 31, 151–175. 10.1146/annurev.biophys.31.082901.134259 [DOI] [PubMed] [Google Scholar]
  68. Miyasho T., Takagi H., Suzuki H., Watanabe S., Inoue M., Kudo Y., et al. (2001). Low-threshold potassium channels and a low-threshold calcium channel regulate Ca2+ spike firing in the dendrites of cerebellar Purkinje neurons: a modeling study. Brain Res. 891, 106–115. 10.1016/S0006-8993(00)03206-6 [DOI] [PubMed] [Google Scholar]
  69. Moraru I. I., Schaff J. C., Slepchenko B. M., Blinov M. L., Morgan F., Lakshminarayana A., et al. (2008). Virtual Cell modelling and simulation software environment. IET Syst. Biol. 2, 352–362. 10.1049/iet-syb:20080102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Musova Z., Sedlacek Z., Mazanec R., Klempir J., Roth J., Plevova P., et al. (2013). Spinocerebellar ataxias type 8, 12, and 17 and dentatorubro-pallidoluysian atrophy in Czech ataxic patients. Cerebellum 12, 155–161. 10.1007/s12311-012-0403-5 [DOI] [PubMed] [Google Scholar]
  71. Nakamura K., Jeong S., Uchihara T., Anno M., Nagashima K., Nagashima T., et al. (2001). SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum. Mol. Genet. 10, 1441–1448. 10.1093/hmg/10.14.1441 [DOI] [PubMed] [Google Scholar]
  72. Novak M., Davis M., Li A., Goold R., Tabrizi S., Sweeney M., et al. (2010a). PAW32 ITPR1 gene deletion causes spinocerebellar ataxia 15/16: a genetic, clinical and radiological description of a novel kindred. J. Neurol. Neurosurg. Psychiatr. 81, e32. 10.1136/jnnp.2010.226340.60 [DOI] [PubMed] [Google Scholar]
  73. Novak M., Sweeney M., Li A., Treacy C., Chandrashekar H., Giunti P., et al. (2010b). An ITPR1 gene deletion causes spinocerebellar ataxia 15/16: a genetic, clinical and radiological description. Mov. Disord. 25, 2176–2182. 10.1002/mds.23223 [DOI] [PubMed] [Google Scholar]
  74. Ogasawara H., Doi T., Kawato M. (2008). Systems biology perspectives on cerebellar long-term depression. Neurosignals 16, 300–317. 10.1159/000123040 [DOI] [PubMed] [Google Scholar]
  75. Ogura H., Matsumoto M., Mikoshiba K. (2001). Motor discoordination in mutant mice heterozygous for the type 1 inositol 1,4,5-trisphosphate receptor. Behav. Brain Res. 122, 215–219. 10.1016/S0166-4328(01)00187-5 [DOI] [PubMed] [Google Scholar]
  76. Orr H., Chung M., Banfi S., Kwiatkowski T. J., Servadio A., Beaudet A., et al. (1993). Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat. Genet. 4, 221–226. 10.1038/ng0793-221 [DOI] [PubMed] [Google Scholar]
  77. Orr H. T. (2012). Cell biology of spinocerebellar ataxia. J. Cell Biol. 197, 167–177. 10.1083/jcb.201105092 [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Pulst S., Nechiporuk A., Nechiporuk T., Gispert S., Chen X., Lopes-Cendes I., et al. (1996). Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat. Genet. 14, 269–276. 10.1038/ng1196-269 [DOI] [PubMed] [Google Scholar]
  79. Raut S. S., Chandra S., Shum J., Finol E. A. (2013). The role of geometric and biomechanical factors in abdominal aortic aneurysm rupture risk assessment. Ann. Biomed. Eng. 41, 1459–1477. 10.1007/s10439-013-0786-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Reich S. D., Steinberg F., Bachur N. R., Riggs C. E., Goebel R., Berman M. (1979). Mathematical model for adriamycin (doxorubicin) pharmacokinetics. Cancer Chemother. Pharmacol. 3, 125–131. 10.1007/BF00254984 [DOI] [PubMed] [Google Scholar]
  81. Rodríguez-Quiroga S. A., Gonzalez-Morón D., Garretto N., Kauffman M. A. (2013). Huntington's disease masquerading as spinocerebellar ataxia. BMJ Case Rep. 2013:bcr2012008380. 10.1136/bcr-2012-008380 [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Sandonà D., Scolari A., Mikoshiba K., Volpe P. (2003). Subcellular distribution of Homer 1b/c in relation to endoplasmic reticulum and plasma membrane proteins in Purkinje neurons. Neurochem. Res. 28, 1151–1158. 10.1023/A:1024264025401 [DOI] [PubMed] [Google Scholar]
  83. Sarkisov D., Wang S. (2008). Order-dependent coincidence detection in cerebellar Purkinje neurons at the inositol trisphosphate receptor. J. Neurosci. 28, 133–142. 10.1523/JNEUROSCI.1729-07.2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Sausbier M., Hu H., Arntz C., Feil S., Kamm S., Adelsberger H., et al. (2004). Cerebellar ataxia and Purkinje cell dysfunction caused by Ca2+-activated K+ channel deficiency. Proc. Natl. Acad. Sci. U.S.A. 101, 9474–9478. 10.1073/pnas.0401702101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Schaff J., Slepchenko B., Loew L. (2000). Physiological modeling with virtual cell framework. Meth. Enzymol. 321, 1–23. 10.1016/S0076-6879(00)21184-1 [DOI] [PubMed] [Google Scholar]
  86. Schöls L., Bauer P., Schmidt T., Schulte T., Riess O. (2004). Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 3, 291–304. 10.1016/S1474-4422(04)00737-9 [DOI] [PubMed] [Google Scholar]
  87. Schuler-Faccini L., Osorio C. M., Romariz F., Paneque M., Sequeiros J., Jardim L. B. (2014). Genetic counseling and presymptomatic testing programs for Machado-Joseph Disease: lessons from Brazil and Portugal. Genet. Mol. Biol. 37(Suppl. 1), 263–270. 10.1590/S1415-47572014000200012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Serra H., Byam C., Lande J., Tousey S., Zoghbi H., Orr H. (2004). Gene profiling links SCA1 pathophysiology to glutamate signaling in Purkinje cells of transgenic mice. Hum. Mol. Genet. 13, 2535–2543. 10.1093/hmg/ddh268 [DOI] [PubMed] [Google Scholar]
  89. Shakkottai V. G., do Carmo Costa M., Dell'Orco J. M., Sankaranarayanan A., Wulff H., Paulson H. L. (2011). Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J. Neurosci. 31, 13002–13014. 10.1523/JNEUROSCI.2789-11.2011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Shiraishi Y., Mizutani A., Yuasa S., Mikoshiba K., Furuichi T. (2004). Differential expression of Homer family proteins in the developing mouse brain. J. Comp. Neurol. 473, 582–599. 10.1002/cne.20116 [DOI] [PubMed] [Google Scholar]
  91. Slepchenko B. M., Loew L. M. (2010). Use of virtual cell in studies of cellular dynamics. Int. Rev. Cell Mol. Biol. 283, 1–56. 10.1016/S1937-6448(10)83001-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Smeets C. J., Verbeek D. S. (2014). Cerebellar ataxia and functional genomics: identifying the routes to cerebellar neurodegeneration. Biochim. Biophys. Acta. 1842, 2030–2038. 10.1016/j.bbadis.2014.04.004 [DOI] [PubMed] [Google Scholar]
  93. Soudah E., Ng E. Y., Loong T. H., Bordone M., Pua U., Narayanan S. (2013). CFD modelling of abdominal aortic aneurysm on hemodynamic loads using a realistic geometry with CT. Comput. Math. Methods Med. 2013:472564. 10.1155/2013/472564 [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Spence J. L., Wallihan S. (2012). Computational prediction of the polyQ and CAG repeat spinocerebellar ataxia network based on sequence identity to untranslated regions. Gene 509, 273–281. 10.1016/j.gene.2012.07.068 [DOI] [PubMed] [Google Scholar]
  95. Storey E., Gardner R., Knight M., Kennerson M., Tuck R., Forrest S., et al. (2001). A new autosomal dominant pure cerebellar ataxia. Neurology 57, 1913–1915. 10.1212/WNL.57.10.1913 [DOI] [PubMed] [Google Scholar]
  96. Street V., Bosma M., Demas V., Regan M., Lin D., Robinson L., et al. (1997). The type 1 inositol 1,4,5-trisphosphate receptor gene is altered in the opisthotonos mouse. J. Neurosci. 17, 635–645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Suzuki K., Zhou J., Sato T., Takao K., Miyagawa T., Oyake M., et al. (2012). DRPLA transgenic mouse substrains carrying single copy of full-length mutant human DRPLA gene with variable sizes of expanded CAG repeats exhibit CAG repeat length- and age-dependent changes in behavioral abnormalities and gene expression profiles. Neurobiol. Dis. 46, 336–350. 10.1016/j.nbd.2012.01.014 [DOI] [PubMed] [Google Scholar]
  98. Takagishi Y., Oda S., Hayasaka S., Dekker-Ohno K., Shikata T., Inouye M., et al. (1996). The dilute-lethal (dl) gene attacks a Ca2+ store in the dendritic spine of Purkinje cells in mice. Neurosci. Lett. 215, 169–172. 10.1016/0304-3940(96)12967-0 [DOI] [PubMed] [Google Scholar]
  99. Tang T., Guo C., Wang H., Chen X., Bezprozvanny I. (2009). Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model. J. Neurosci. 29, 1257–1266. 10.1523/JNEUROSCI.4411-08.2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Tang T., Tu H., Chan E., Maximov A., Wang Z., Wellington C., et al. (2003a). Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39, 227–239. 10.1016/S0896-6273(03)00366-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Tang T., Tu H., Wang Z., Bezprozvanny I. (2003b). Modulation of type 1 inositol (1,4,5)-trisphosphate receptor function by protein kinase a and protein phosphatase 1alpha. J. Neurosci. 23, 403–415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Tonelli A., D'Angelo M., Salati R., Villa L., Germinasi C., Frattini T., et al. (2006). Early onset, non fluctuating spinocerebellar ataxia and a novel missense mutation in CACNA1A gene. J. Neurol. Sci. 241, 13–17. 10.1016/j.jns.2005.10.007 [DOI] [PubMed] [Google Scholar]
  103. Trottier Y., Biancalana V., Mandel J. (1994). Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset. J. Med. Genet. 31, 377–382. 10.1136/jmg.31.5.377 [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Tu H., Tang T., Wang Z., Bezprozvanny I. (2004). Association of type 1 inositol 1,4,5-trisphosphate receptor with AKAP9 (Yotiao) and protein kinase A. J. Biol. Chem. 279, 19375–19382. 10.1074/jbc.M313476200 [DOI] [PubMed] [Google Scholar]
  105. Tu J., Xiao B., Yuan J., Lanahan A., Leoffert K., Li M., et al. (1998). Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron 21, 717–726. 10.1016/S0896-6273(00)80589-9 [DOI] [PubMed] [Google Scholar]
  106. Ueda T., Seki T., Katanazaka K., Sekiguchi K., Kobayashi K., Kanda F., et al. (2013). A novel mutation in the C2 domain of protein kinase C gamma associated with spinocerebellar ataxia type 14. J. Neurol. 260, 1664–1666. 10.1007/s00415-013-6916-0 [DOI] [PubMed] [Google Scholar]
  107. van de Leemput J., Chandran J., Knight M., Holtzclaw L., Scholz S., Cookson M., et al. (2007). Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet. 3:e108. 10.1371/journal.pgen.0030108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. van Gaalen J., Vermeer S., van Veluw M., van de Warrenburg B. P., Dooijes D. (2013). A de novo SCA14 mutation in an isolated case of late-onset cerebellar ataxia. Mov. Disord. 28, 1902–1903. 10.1002/mds.25572 [DOI] [PubMed] [Google Scholar]
  109. Velázquez-Pérez L., Rodríguez-Labrada R., Canales-Ochoa N., Montero J. M., Sánchez-Cruz G., Aguilera-Rodríguez R., et al. (2014a). Progression of early features of spinocerebellar ataxia type 2 in individuals at risk: a longitudinal study. Lancet Neurol. 13, 482–489. 10.1016/S1474-4422(14)70027-4 [DOI] [PubMed] [Google Scholar]
  110. Velázquez-Pérez L., Rodríguez-Labrada R., Cruz-Rivas E. M., Fernández-Ruiz J., Vaca-Palomares I., et al. (2014b). Comprehensive study of early features in spinocerebellar Ataxia 2: delineating the prodromal stage of the disease. Cerebellum. 13, 568–579. 10.1007/s12311-014-0574-3 [DOI] [PubMed] [Google Scholar]
  111. Vig P., Subramony S., McDaniel D. (2001). Calcium homeostasis and spinocerebellar ataxia-1 (SCA-1). Brain Res. Bull. 56, 221–225. 10.1016/S0361-9230(01)00595-0 [DOI] [PubMed] [Google Scholar]
  112. Wagner W., Hammer J. R. (2003). Myosin V and the endoplasmic reticulum: the connection grows. J. Cell Biol. 163, 1193–1196. 10.1083/jcb.200311077 [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Wang S., Denk W., Häusser M. (2000). Coincidence detection in single dendritic spines mediated by calcium release. Nat. Neurosci. 3, 1266–1273. 10.1038/81792 [DOI] [PubMed] [Google Scholar]
  114. Xu C., Watras J., Loew L. (2003). Kinetic analysis of receptor-activated phosphoinositide turnover. J. Cell Biol. 161, 779–791. 10.1083/jcb.200301070 [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Yue Q., Jen J., Nelson S., Baloh R. (1997). Progressive ataxia due to a missense mutation in a calcium-channel gene. Am. J. Hum. Genet. 61, 1078–1087. 10.1086/301613 [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Zecevic N., Milosevic A., Ehrlich B. (1999). Calcium signaling molecules in human cerebellum at midgestation and in ataxia. Early Hum. Dev. 54, 103–116. 10.1016/S0378-3782(98)00090-5 [DOI] [PubMed] [Google Scholar]
  117. Zhan W., Xu X. Y. (2013). A mathematical model for thermosensitive liposomal delivery of Doxorubicin to solid tumour. J. Drug Deliv. 2013:172529. 10.1155/2013/172529 [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Zhang H., Li Q., Graham R., Slow E., Hayden M., Bezprozvanny I. (2008). Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol. Dis. 31, 80–88. 10.1016/j.nbd.2008.03.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Zhuchenko O., Bailey J., Bonnen P., Ashizawa T., Stockton D., Amos C., et al. (1997). Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat. Genet. 15, 62–69. 10.1038/ng0197-62 [DOI] [PubMed] [Google Scholar]
  120. Zuliani L., Sabater L., Saiz A., Baiges J., Giometto B., Graus F. (2007). Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia. Neurology 68, 239–240. 10.1212/01.wnl.0000251308.79366.f9 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (128.3KB, DOCX)
Click here for additional data file. (2.3MB, TIF)
Click here for additional data file. (3.3MB, TIF)

Articles from Frontiers in Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES